Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests
- 1 January 2014
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 52 (6), 835-844
- https://doi.org/10.1515/cclm-2013-0936
Abstract
Background: In recent years, several selectively acting anticoagulants, including the direct thrombin inhibitors (DTI; argatroban, dabigatran) and the factor Xa inhibitors (rivaroxaban, apixaban, fondaparinux), have been developed. With their clinical application increasing, it is of interest to evaluate their interference with classical haemostaseological point-of-care tests. Additionally, the effect of the investigated anticoagulants on platelet function tests will come increasingly more into focus for monitoring not only hereditary platelet dysfunction, but also antiplatelet therapy. Methods: Blood samples from healthy volunteers were spiked with therapeutic and supratherapeutic concentrations of the drugs listed above and investigated with regard to their effects on the following POCTs: activated clotting time (ACT), thromboelastometry with ROTEM (R), PFA (R) and Multiplate (R). Light-transmission aggregometry (LTA) was used for a platelet function assay. Results: At supratherapeutic concentrations, ACT and ROTEM (R) analysis were always influenced after administration of the drugs listed above (except fondaparinux in EXTEM-CT). Therapeutic concentrations showed differential effects on these assays. LTA measurements revealed a distinct decrease in alpha-thrombin-induced platelet aggregation for both DTIs (therapeutic and supratherapeutic concentrations), while argatroban reduced platelet function in supratherapeutic concentrations. None of the drugs seemed to have any influence on PFA (R) or Multiplate (R). Conclusions: Selective thrombin and factor Xa inhibitors exhibit distinct effects on POCTs and platelet function tests. This must be considered in assessing assay results when taking medical decisions.Keywords
This publication has 22 references indexed in Scilit:
- Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and ApixabanCanadian Journal of Cardiology, 2013
- Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levelsJournal of Thrombosis and Haemostasis, 2013
- Impact of dabigatran on a large panel of routine or specific coagulation assaysThrombosis and Haemostasis, 2012
- UPLC MS/MS assay for routine quantification of dabigatran – A direct thrombin inhibitor – In human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2012
- Historical perspective and future direction of coagulation researchJournal of Thrombosis and Haemostasis, 2011
- Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assaysJournal of Thrombosis and Haemostasis, 2011
- Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assaysThrombosis and Haemostasis, 2011
- Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombinThrombosis and Haemostasis, 2010
- An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin timeActa Anaesthesiologica Scandinavica, 2009
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic SurgeryClinical Pharmacokinetics, 2008